Crestwood Advisors Group LLC Sells 76,979 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Crestwood Advisors Group LLC reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 44.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 95,316 shares of the medical research company’s stock after selling 76,979 shares during the quarter. Crestwood Advisors Group LLC owned about 0.05% of IQVIA worth $18,731,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in IQV. Smith Group Asset Management LLC acquired a new position in IQVIA in the fourth quarter valued at approximately $1,616,000. Simplify Asset Management Inc. raised its position in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Hickory Asset Management Inc. bought a new position in shares of IQVIA in the 4th quarter worth $941,000. Finally, Fifth Third Bancorp increased its holdings in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after purchasing an additional 1,521 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on IQV. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Bank of America lowered their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. The Goldman Sachs Group decreased their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $251.22.

Insider Activity

In other news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Down 1.6 %

Shares of IQV stock opened at $190.94 on Monday. The firm’s fifty day moving average price is $199.57 and its two-hundred day moving average price is $216.25. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The firm has a market capitalization of $33.62 billion, a P/E ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.